贝达喹啉、德拉马尼、利奈唑胺和氯法齐明治疗准广泛耐药结核病
这项前瞻性研究评估贝达喹啉、德拉马尼、利奈唑胺和氯法齐明全口服方案治疗耐多药结核病(对氟喹诺酮类或二线注射剂额外耐药)成人患者24-36周的有效性与安全性。165例入组者中158例为MDR-TBFQ+,治疗结束时153例可评估者中139例(91%)获得有利结局,14例(9%)不利结局;52%发生骨髓抑制,42%周围神经病变,无QTcF延长>500毫秒。
要点
- 全口服贝达喹啉+德拉马尼+利奈唑胺+氯法齐明方案治疗24-36周,91%患者获有利结局。
- 52%发生骨髓抑制,42%周围神经病变,无QTcF延长>500毫秒,心脏毒性轻微。
- 随访48周时131例维持治疗成功,多数不良事件缓解。
核心结论
- 24-36周全口服贝达喹啉、德拉马尼、利奈唑胺和氯法齐明方案在伴额外耐药的肺结核MDR-TB患者中取得满意的有利结局,心脏毒性轻微,骨髓抑制常见但可早期发现并成功处理。
研究设计与样本
- 前瞻性研究,纳入165例成人肺结核MDR-TBFQ+或/和MDR-TBSLI+患者,给予贝达喹啉、德拉马尼、利奈唑胺和氯法齐明全口服方案治疗24-36周。
- 主要结局为治疗结束时有利反应,定义为间隔4周连续两次培养阴性;不利结局包括治疗期间细菌学或临床失败。
主要发现
- 165例入组者中158例为MDR-TBFQ+;排除12例因基线药敏和培养阴性后,153例可评估者中139例(91%)获有利结局,14例(9%)为不利结局(4例死亡、7例更换治疗、2例细菌学失败、1例退出)。
- 治疗期间85例(52%)发生骨髓抑制,69例(42%)报告周围神经病变,无QTcF延长>500毫秒。
- 随访48周时131例维持治疗成功,多数不良事件缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) remain low globally. Availability of newer drugs has given scope to develop regimens that can be patient-friendly, less toxic, with improved outcomes. We proposed to determine the effectiveness of an entirely oral, short-course regimen with Bedaquiline and Delamanid in treating MDR-TB with additional resistance to fluoroquinolones (MDR-TBFQ+) or second-line injectable (MDR-TBSLI+). METHODS: We prospectively determined the effectiveness and safety of combining two new drugs with two repurposed drugs - Bedaquiline, Delamanid, Linezolid, and Clofazimine for 24-36 weeks in adults with pulmonary MDR-TBFQ+ or/and MDR-TBSLI+. The primary outcome was a favorable response at end of treatment, defined as two consecutive negative cultures taken four weeks apart. The unfavorable outcomes included bacteriologic or clinical failure during treatment period. RESULTS: Of the 165 participants enrolled, 158 had MDR-TBFQ+. At the end of treatment, after excluding 12 patients due to baseline drug susceptibility and culture negatives, 139 of 153 patients (91%) had a favorable outcome. Fourteen patients (9%) had unfavorable outcomes: four deaths, seven treatment changes, two bacteriological failures, and one withdrawal. During treatment, 85 patients (52%) developed myelosuppression, 69 (42%) reported peripheral neuropathy, and none had QTc(F) prolongation >500msec. At 48 weeks of follow-up, 131 patients showed sustained treatment success with the resolution of adverse events in the majority. CONCLUSION: After 24-36 weeks of treatment, this regimen resulted in a satisfactory favorable outcome in pulmonary MDR-TB patients with additional drug resistance. Cardiotoxicity was minimal, and myelosuppression, while common, was detected early and treated successfully.
引用
- Padmapriyadarsini C, Vohra V, Bhatnagar A, et al. Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2022. PMID: 35767251. doi:10.1093/cid/ciac528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。